Jeremy D. Gale
Pfizer (United States)(US)
Publications by Year
Research Areas
Gastrointestinal motility and disorders, Inflammatory Bowel Disease, Microscopic Colitis, Neuropeptides and Animal Physiology, Gastroesophageal reflux and treatments
Most-Cited Works
- → Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals(2020)747 cited
- → Effect of a second-generation α 2 δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome(2007)200 cited
- → GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity(1996)145 cited
- → GR113808: a novel, selective antagonist with high affinity at the 5‐HT4 receptor(1994)142 cited
- → The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040(1995)122 cited
- → Online High-Flow Peptide Immunoaffinity Enrichment and Nanoflow LC-MS/MS: Assay Development for Total Salivary Pepsin/Pepsinogen(2010)96 cited
- → Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study(2023)83 cited
- → Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy(2016)65 cited
- → Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation(2012)59 cited
- → Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study(2015)56 cited